Incyte Corporation

Stocks

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 01:30:00 17/06/2026 am IST			After hours 05:26:02 am
99.75 ^USD	-2.19%		100.60	+0.85%

15/06	Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial	MT
15/06	Mirum Pharmaceuticals, Inc. and Incyte Report Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	CI

Transcript : Incyte Corporation Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 10

Published on 05/19/2026 at 09:05 pm IST - Modified on 05/19/2026 at 11:05 pm IST

S&P Capital IQ

Presenter Speech
Brian Abrahams (Analysts)

[Audio Gap] featured company Incyte, presented by their Chief Medical Officer, Steven Stein. So thanks so much for joining us, Steven.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Incyte Corporation

15/06	Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial	MT
15/06	Mirum Pharmaceuticals, Inc. and Incyte Report Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	CI
13/06	Incyte Announces Updated Clinical Data From Two Phase 1 Studies Evaluating INCA033989 In Patients With MutCALR-Expressing Myeloproliferative Neoplasms	CI
13/06	Incyte Presents Results from Pivotal Phase 3 Frontmind Trial of Tafasitamab Combination At Eha 2026 Plenary	CI
11/06	Guggenheim Lifts Price Target on Incyte to $136 From $130, Maintains Buy Rating	MT
11/06	William O'Neil Initiates Incyte at Buy	MT
11/06	Analyst recommendations: Chewy, CME Group, Ford Motor, Fortinet, Humana…
09/06	HC Wainwright Adjusts Incyte Price Target to $140 From $135, Maintains Buy Rating	MT
09/06	Incyte Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08:40 AM
09/06	Health Care Ticks Down Amid Deal Activity - Health Care Roundup	DJ
09/06	Incyte Insider Sold Shares Worth $263,900, According to a Recent SEC Filing	MT
09/06	Oppenheimer Adjusts Price Target on Incyte to $107 From $90, Maintains Perform Rating	MT
08/06	Incyte To Acquire Vega Therapeutics For Up To $2 Billion	MT
08/06	Incyte Corporation, Vega Therapeutics, Inc. - M&A Call
08/06	Incyte Corporation entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.	CI